AbbVie today announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented in an oral session at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting (San Juan, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results